模块化半骨盆假体用于髋臼周围肿瘤的重建。

Reconstruction with modular hemipelvic prostheses for periacetabular tumor.

作者信息

Guo Wei, Li Dasen, Tang Xiaodong, Yang Yi, Ji Tao

机构信息

Musculoskeletal Tumor Center, People's Hospital, Peking University, Beijing, China.

出版信息

Clin Orthop Relat Res. 2007 Aug;461:180-8. doi: 10.1097/BLO.0b013e31806165d5.

Abstract

Periacetabular resections for primary bone sarcoma and metastatic disease require reconstruction to restore weight-bearing along anatomic axes. We designed a modular hemipelvic prosthetic system to reconstruct the pelvis and evaluated the early clinical outcome of the prosthesis using 3-year survival rate, local recurrence rate, Musculoskeletal Tumor Society (MSTS) 93 function score, and complications. We retrospectively reviewed 28 patients who had pelvic tumor resections and reconstructions using the new hemipelvic prostheses between 2001 and 2005. Sixteen (57.1%) patients had Types II and III (periacetabular and pubis) pelvic resections, seven had Types I and II (periacetabular and ilium) pelvic resections, and five had Type II (periacetabular) pelvic resection. Six patients with osteosarcoma had chemotherapy. None received radiation therapy. Patient survival status, function, and complications were evaluated at a mean followup of 30 months (range, 10-59 months). Fifteen patients were free of disease, eight patients died of disease, and five patients were alive with disease. The overall survival rate was 67.1% at 3 years. Twenty-five percent had local recurrence and 21% had metastasis. The mean MSTS 93 score was 60. Deep infection occurred in four patients; dislocation occurred in one patient. The results are encouraging because of the acceptable complication rate and satisfactory functional outcome.

摘要

用于原发性骨肉瘤和转移性疾病的髋臼周围切除术需要进行重建,以沿解剖轴恢复负重功能。我们设计了一种模块化半骨盆假体系统来重建骨盆,并使用3年生存率、局部复发率、肌肉骨骼肿瘤学会(MSTS)93功能评分和并发症来评估该假体的早期临床结果。我们回顾性分析了2001年至2005年间28例使用新型半骨盆假体进行骨盆肿瘤切除和重建的患者。16例(57.1%)患者接受了II型和III型(髋臼周围和耻骨)骨盆切除术;7例接受了I型和II型(髋臼周围和髂骨)骨盆切除术;5例接受了II型(髋臼周围)骨盆切除术;6例骨肉瘤患者接受了化疗;均未接受放疗。在平均30个月(范围10 - 59个月)的随访中评估患者的生存状态、功能和并发症。15例患者无疾病,8例患者死于疾病,5例患者带瘤生存。3年总生存率为67.1%;25%发生局部复发,21%发生转移;MSTS 93功能评分平均为60分;4例患者发生深部感染,1例患者发生脱位。由于并发症发生率可接受且功能结果令人满意,结果令人鼓舞。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索